Story

Abcellera Stock Surges Over 30% on Positive Phase 2 Menopause Drug Data

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
Abcellera Stock Surges Over 30% on Positive Phase 2 Menopause Drug Data
Text size
Background

Abcellera Biologics (NASDAQ: ABCL) stock surged 30.3% in pre-open trading after the company reported that its drug candidate, ABCL635, met the primary efficacy endpoint in a Phase 2 clinical trial. The trial evaluated the antibody for treating moderate-to-severe vasomotor symptoms, commonly known as hot flashes, associated with menopause.

Trial Results Detail Clinical Success

The randomized, double-blind, placebo-controlled study enrolled 92 postmenopausal women. According to the company, the trial demonstrated a 83% mean reduction in hot flash frequency at week four for patients receiving ABCL635. The treatment group experienced a reduction of 8.8 events per day, compared to a 3.5 event-per-day reduction for the placebo group.

ABCL635 is a potential first-in-class, non-hormonal antibody that targets the neurokinin 3 receptor (NK3R). This positive readout marks the first Phase 2 data from AbCellera’s GPCR and ion channel platform, a significant milestone for its internal drug development pipeline that investors have been closely monitoring.

Sample IUX Markets – In-articleAd

Market Reaction and Context

The sharp upward move in Abcellera's stock was entirely company-specific, standing in contrast to the broader market, which saw the S&P 500, Dow Jones, and Nasdaq all trading modestly lower in the pre-market session. The positive clinical news propelled the stock above its previous 52-week high, resetting investor expectations for the drug's commercial potential.

The announcement follows recent positive sentiment from Wall Street analysts. In the days leading up to the data release, Cantor Fitzgerald raised its price target on the stock to $12, Stifel lifted its target to $9, and Piper Sandler reiterated a Buy rating. The company's strong financial position, including $567 million in cash and over $675 million in total available liquidity, further supports its ability to fund its ongoing pipeline development.

Read next

More on Stocks
Back to latest news

LATEST